Previous close | 4.1000 |
Open | 4.0000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 100.00 |
Expiry date | 2024-06-21 |
Day's range | 4.0000 - 4.1000 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Abbott (ABT) closed the most recent trading day at $104.29, moving +0.64% from the previous trading session.
Since its split from Abbott Laboratories in 2013, AbbVie (NYSE: ABBV) has been the third best-performing stock in terms of total returns on capital (assuming the dividend was reinvested) on the esteemed list of Dividend Kings. AbbVie's top-shelf performance has been due to two main factors. First up, the company successfully expanded Humira's label at a breakneck pace over this period, transforming it into the world's first pharma product to exceed $20 billion a year in sales.
According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?